Polivy was approved in combination with Roche’s older drug Rituxan and a chemotherapy agent for adult patients with advanced diffuse large B-cell lymphoma (DLBCL) whose cancer has worsened despite at least two previous lines of therapy.
Roche’s combo lymphoma treatment wins U.S. FDA approval
More from Industry NewsMore posts in Industry News »
- Clover says its COVID-19 vaccine candidate 67% effective in large trial
- Britain begins trial of multivariant COVID-19 vaccine booster
- Intranasal vaccine phase-II trials may end next month: Bharat Biotech
- Guardant Health’s comprehensive liquid biopsy test, Guardant360, provides quick and reliable treatment decisions for patients with advanced-stage cancer